- Lodoxamidetromethamine
-
- $15.00 / 1KG
-
2021-07-02
- CAS:63610-09-3
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Lodoxamidetromethamine
-
- $1.00 / 25Kg/Drum
-
2019-10-30
- CAS:63610-09-3
- Min. Order: 25Kg/Drum
- Purity: 99.00%
- Supply Ability: 1ton
- Lodoxamidetromethamine
-
- $1.00 / 1KG
-
2019-07-06
- CAS:63610-09-3
- Min. Order: 1KG
- Purity: 95%
- Supply Ability: 500kg
|
| Lodoxamidetromethamine Basic information |
Product Name: | Lodoxamidetromethamine | Synonyms: | Lodoxamidetromethamine;LodoxaMide troMethaMineon;AlMide;LodoxaMide troMetaMol;LodoxaMide troMethaMine salt;U-42585-E;Lodoxamide tromethamine (U 42585 E);2-Amino-2-(hydroxymethyl)propane-1,3-diol hemi(2,2'-((2-chloro-5-cyano-1,3-phenylene)bis(azanediyl))bis(2-oxoacetate)) | CAS: | 63610-09-3 | MF: | C15H17ClN4O9 | MW: | 432.77 | EINECS: | | Product Categories: | API | Mol File: | 63610-09-3.mol | ![Lodoxamidetromethamine Structure](CAS/GIF/63610-09-3.gif) |
| Lodoxamidetromethamine Chemical Properties |
storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | solubility | DMSO: 20 mg/mL (36.11 mM and warming) | form | Solid | color | White to light yellow |
| Lodoxamidetromethamine Usage And Synthesis |
Description | Lodoxamide tromethamine was launched as an ophthalmic formulation for the
treatment of allergic conjunctivitis. It appears to act as a mast cell stabilizer inhibiting
degranulation and the release of histamine and other vasoactive products in a similar
manner to sodium cromoglycate. The compound is also under investigation as an
orally active antiallergic/antiasthmatic agent. | Originator | Upjohn (U.S.A.) | Uses | cataract treatment | Brand name | Alomide (Alcon);Almide. | General Description | Lodoxamidetromethamine, N, N -(2-chloro-5-cyano-m-phenylene)dioxamicacid (Alomide), is a white crystalline, water-solublepowder. The only significant structural similarity betweenlodoxamide and cromolyn and nedocromil is the presence oftwo acidic groups. Lodoxamide is indicated in the treatmentof the ocular disorders including vernal keratoconjunctivitis,vernal conjunctivitis, and vernal keratitis. Lodoxamide isavailable as a 0.1% solution, with each milliliter containing1.78 mg of lodoxamide tromethamine equivalent to 1 mg oflodoxamide. The solution contains the preservative benzalkoniumchloride (0.007%) as well as mannitol, hydroxypropylmethylcellulose, sodium citrate, citric acid, edetatedisodium, tyloxapol, hydrochloric acid and/or sodium hydroxide(to adjust pH), and purified water. The dose for adults and children older than 2 years of ageis 1 to 2 drops in each affected eye 4 times daily for up to 3months. The most frequently reported ocular adverse experienceswere transient burning, stinging, or discomfort oninstillation. |
| Lodoxamidetromethamine Preparation Products And Raw materials |
|